TY - JOUR
KW - Administration, Sublingual
KW - Analgesics, Opioid/administration & dosage/adverse effects/blood/chemistry
KW - Biological Availability
KW - Biotransformation
KW - Buprenorphine/administration & dosage/adverse effects/analogs & derivatives/blood/chemistry
KW - Drug Compounding
KW - Freeze Drying
KW - Humans
KW - Lung/drug effects/physiopathology
KW - Opiate Substitution Treatment/adverse effects
KW - Opioid-Related Disorders/blood/diagnosis/drug therapy
KW - Respiration/drug effects
KW - Respiratory Insufficiency/chemically induced/diagnosis/physiopathology
KW - Risk Factors
KW - Solubility
KW - Tablets
KW - Treatment Outcome
AU - John Strang
AU - Alastair Knight
AU - Shelagh Baillie
AU - Kylie Reed
AU - Karolina Bogdanowicz
AU - James Bell
A1 - 
AB - OBJECTIVES: To investigate plasma levels of buprenorphine and norbuprenorphine and their relationship to respiratory depression. MATERIALS AND METHODS: Opioid-dependent subjects were randomized 2 : 1 to novel lyophilized rapid-disintegrating tablet ("bup-lyo") or standard sublingual buprenorphine tablet ("bup-SL"). Measurements included oximetry scores and linked plasma buprenorphine and norbuprenorphine levels. RESULTS: Respiratory depression (cumulative duration of SpO2  30 min) of buprenorphine and particularly with norbuprenorphine. A lower buprenorphine/norbuprenorphine ratio was predictive of respiratory depression. The mean (SD) observed ratio was significantly higher for "bup-lyo" (3.4 (2.8)) compared to "bup-SL" (1.7 (0.77)), p < 0.0001. CONCLUSION: Exploratory investigation found respiratory depression more strongly associated with norbuprenorphine than with buprenorphine. This accords with animal studies..
BT - International journal of clinical pharmacology and therapeutics
C5 - Opioids & Substance Use
CP - 2
CY - Germany
DO - 10.5414/CP203118
IS - 2
JF - International journal of clinical pharmacology and therapeutics
LA - eng
M1 - Journal Article
N2 - OBJECTIVES: To investigate plasma levels of buprenorphine and norbuprenorphine and their relationship to respiratory depression. MATERIALS AND METHODS: Opioid-dependent subjects were randomized 2 : 1 to novel lyophilized rapid-disintegrating tablet ("bup-lyo") or standard sublingual buprenorphine tablet ("bup-SL"). Measurements included oximetry scores and linked plasma buprenorphine and norbuprenorphine levels. RESULTS: Respiratory depression (cumulative duration of SpO2  30 min) of buprenorphine and particularly with norbuprenorphine. A lower buprenorphine/norbuprenorphine ratio was predictive of respiratory depression. The mean (SD) observed ratio was significantly higher for "bup-lyo" (3.4 (2.8)) compared to "bup-SL" (1.7 (0.77)), p < 0.0001. CONCLUSION: Exploratory investigation found respiratory depression more strongly associated with norbuprenorphine than with buprenorphine. This accords with animal studies..
PP - Germany
PY - 2018
SN - 0946-1965; 0946-1965
SP - 81
EP - 85
EP - 
T1 - Norbuprenorphine and respiratory depression: Exploratory analyses with new lyophilized buprenorphine and sublingual buprenorphine
T2 - International journal of clinical pharmacology and therapeutics
TI - Norbuprenorphine and respiratory depression: Exploratory analyses with new lyophilized buprenorphine and sublingual buprenorphine
U1 - Opioids & Substance Use
U2 - 29231163
U3 - 10.5414/CP203118
VL - 56
VO - 0946-1965; 0946-1965
Y1 - 2018
Y2 - Feb
ER -